Loblaw Companies Limited — the price of durable grocery margins
Our maximum entry price is C$33.36 per share. Loblaw (TSX: L, Consumer Staples) closed at C$70.92 on November 19, 2026, so we would wait. Pharmacy is growing, but at our base discount rate the price requires an enduring improvement in retail cash margins. Using the last year of observed market risk raises the entry to C$90.29 and flips the decision; the three-year estimate gives C$66.79 and still says wait. Loblaw TSX daily closing prices
- Market close (CAD)
- 70.92
- Base fair value (CAD/share)
- 37.89
Company details
- Maximum entry price (CAD/share)
- 33.36
Investment Thesis
Food and pharmacy provide repeat demand while store openings add volume. The crucial investment question is how much of the resulting profit survives rent and store reinvestment. Q3 sales by category and comparable store sales, p. 12 · Highlighted Peralta exhibit Management outlook and gross capital expenditure, p. 28
Market Mispricing
The close implies a sustained 14.86% pre-rent EBITDA margin with our other assumptions fixed. Our 11.2% base is close to the reported Q3 adjusted EBITDA margin of 11.3%. A lower required return or stronger growth could also explain the price. Operating performance and adjusted EBITDA margin, p. 8
Recent Developments
The July PC Financial disposal leaves an equity investment and a loyalty partnership. Continuing retail operations no longer earn the disposed bank’s revenue. Note 9, EQB and other investments, p. 58 Note 4, discontinued earnings and sale gain, p. 54 · Highlighted Peralta exhibit
Earnings Outlook
The issuer expects high-single-digit adjusted EPS growth for 2026. Share repurchases help EPS even when earnings grow more slowly. We value the operating business before assuming future share retirement. Management outlook and gross capital expenditure, p. 28 Note 11, common-share movements, p. 60
Valuation Summary
Ten forward years plus terminal cash flows give C$37.89 per diluted share. A perpetual half-point shortfall in EBITDA margin reduces value to C$33.37 before conservative cent rounding. Calculation
Recommended Action and Entry Price
Wait. The stressed operating value limits entry to C$33.36; the separate five-year return hurdle allows C$33.82. This width is a model conclusion worth challenging against peer prices.
Catalysts
At the next quarterly filing, compare food traffic, pharmacy same-store sales, and capex with the opening of new stores. Volume recovery at stable margins would strengthen the case. Q3 sales by category and comparable store sales, p. 12 · Highlighted Peralta exhibit Management outlook and gross capital expenditure, p. 28
Primary Risks to Thesis
The largest upside risk to a wait decision is a structurally lower required return combined with better cash conversion. A 100 bp lower discount rate alone raises fair value to C$48.81.
Company Overview
Loblaw earns most of its revenue in Canadian food and drug retail. Continuing sales were C$49.39 billion in the first 40 weeks of 2026. Interim earnings and diluted shares, p. 46
Products and Services
Food retail accounted for C$14.05 billion in Q3. Drug sales comprised C$3.20 billion in pharmacy and healthcare and C$2.61 billion in front-store products. Q3 sales by category and comparable store sales, p. 12 · Highlighted Peralta exhibit
Business Model
Stores collect retail receipts while franchise and associate arrangements share store economics. The PC Optimum partnership adds a financial-services connection without retaining the former banking book. Note 9, EQB and other investments, p. 58
Revenue Drivers
Q3 food comparable sales rose 0.6%, pharmacy and healthcare 7.6%, and drug front store 1.6%. Changes in comparable sales and net new space both matter to consolidated growth. Q3 sales by category and comparable store sales, p. 12 · Highlighted Peralta exhibit
Cost Structure
Merchandise cost C$13.64 billion and SG&A C$4.81 billion in Q3. A 50 bp permanent change in pretax cash margin is worth roughly C$4.52 per share here. Interim earnings and diluted shares, p. 46
Operating Levers
Traffic and basket size can offset one another. In Q3 food traffic declined and basket size rose; unit demand provides a stronger test of franchise health than inflation alone. Same-store basket and traffic commentary, p. 13
Distribution
The network adds food stores and pharmacies and requires investment in distribution centres. New locations consume capital before reaching mature sales density. Management outlook and gross capital expenditure, p. 28
Geographic Exposure
Our model treats the disclosed food and drug network as one CAD retail business. The issuer reports category sales; the cited breakdown does not isolate provincial operating profits. Regional profitability remains an uncertainty. Q3 sales by category and comparable store sales, p. 12 · Highlighted Peralta exhibit
Regulatory Environment
Provincial reimbursement policy is an exposure for prescription services. We stress margin rather than assign an unsupported province-specific tariff or profit figure. Q3 sales by category and comparable store sales, p. 12 · Highlighted Peralta exhibit
Industry Structure
Metro and Empire compete for grocery baskets and pharmacy spending. Differences in format, scale and accounting materially affect margin comparisons. Metro earnings and cash operating costs, p. 17 Empire earnings and equity income, p. 27
Growth and Cyclicality
Essential demand softens volume cyclicality, but inflation can lift nominal sales as customers reduce units or trade down. The Q3 traffic and basket split illustrates this divergence. Food retail volume commentary, p. 13
Competitors
Metro pairs grocery and pharmacy, while Empire’s latest quarter includes other income and equity earnings. Compare operating and parent margins before interpreting a valuation premium. Metro earnings and cash operating costs, p. 17 Empire earnings and equity income, p. 27
Market Share
Issuer filings establish relative sales scale, but fiscal periods and business mix differ. They do not supply a common market denominator; no national share percentage enters the valuation. Q3 sales by category and comparable store sales, p. 12 · Highlighted Peralta exhibit Metro earnings and cash operating costs, p. 17 Empire earnings and equity income, p. 27
Competitive Advantages
The combination of loyalty data and repeat pharmacy visits could reduce customer acquisition costs. The EQB agreement preserves the loyalty relationship; the size of a cost advantage is unquantified. Note 9, EQB and other investments, p. 58
Pricing and Cost Position
Loblaw reported a 7.09% Q3 operating margin. Metro’s latest quarter produced about 5.96% on an EBIT-before-net-financing basis. The difference is evidence to investigate, not a perpetual spread to capitalize. Interim earnings and diluted shares, p. 46 Metro earnings and cash operating costs, p. 17
Entry Barriers and Substitutes
Distribution facilities, store networks and pharmacy licences require investment. Discount stores and rival banners still give households substitutes; we fade category growth as the network matures. Management outlook and gross capital expenditure, p. 28 Q3 sales by category and comparable store sales, p. 12 · Highlighted Peralta exhibit
Supplier and Customer Dynamics
Inventory and supplier credit finance part of the retail cycle. Trade payables and other liabilities stood at C$7.62 billion against C$6.88 billion of inventory. The former includes items beyond suppliers. Interim balance sheets, p. 49 · Highlighted Peralta exhibit
Regulation and Structural Risks
Pricing and pharmacy reimbursement pressures could compress cash margin. Use realized gross profit, cash rent and retained cash after capex to detect whether price increases reach shareholders. Interim earnings and diluted shares, p. 46 Interim cash flows, rent and capital purchases, p. 50 · Highlighted Peralta exhibit
Historical Performance
Reported sales rose 6.3% in FY2025, aided by a C$1.138 billion extra week. The report preserves reported history and removes that week from the forecast starting level. FY2025 category sales and 53rd-week adjustment, p. 32 · Highlighted Peralta exhibit
Income Statement Analysis
For the current 40 weeks, EBIT rose to C$3.62 billion from C$3.29 billion on 3.9% revenue growth. The operating line excludes the equity-accounted loss shown below it. Interim earnings and diluted shares, p. 46
Balance Sheet Analysis
The January balance sheet included C$5.66 billion of assets held for sale. Comparing its debt or total assets directly with October without the disposal distorts apparent deleveraging. Annual balance sheets, p. 105 Interim balance sheets, p. 49 · Highlighted Peralta exhibit Note 4, discontinued earnings and sale gain, p. 54 · Highlighted Peralta exhibit
Cash Flow Analysis
Operating cash flow increased C$984 million for the 40 weeks. Working capital used C$235 million versus C$821 million a year earlier, explaining C$586 million of that improvement. Interim cash flows, rent and capital purchases, p. 50 · Highlighted Peralta exhibit
Earnings Quality
Quarterly total diluted EPS was C$1.03, while continuing diluted EPS was C$0.68. Using total EPS as a recurring earnings base would materially overstate the business. Interim earnings and diluted shares, p. 46 Note 4, discontinued earnings and sale gain, p. 54 · Highlighted Peralta exhibit
Nonrecurring Items
Discontinued operations contributed C$401 million, including a C$432 million pretax sale gain net of transaction costs. The model excludes those earnings and values the retained investments once. Note 4, discontinued earnings and sale gain, p. 54 · Highlighted Peralta exhibit Note 9, EQB and other investments, p. 58
Funding and Cash Conversion
Q3 fixed asset and intangible cash purchases totalled C$789 million. The separate capital-investment KPI includes transfers of prepayments; cash-flow timing need not match that KPI. Interim cash flows, rent and capital purchases, p. 50 · Highlighted Peralta exhibit Capital investment definition, p. 8
Key Ratios
Current 40-week EBIT margin was 7.33%, up from 6.92%; the latest 16 weeks alone were 7.09%. These are reported EBIT margins, distinct from the pre-rent EBITDA input. Interim earnings and diluted shares, p. 46
Forward Outlook
Management plans approximately C$2.4 billion of gross capital spending. We start at 3.7% of forecast sales and fade toward 3.2%; lower sustaining needs would raise entry. Management outlook and gross capital expenditure, p. 28
Model Choice
Retail FCFF is appropriate after removing banking activities. Start with category revenue, subtract cash rent and owned-asset depreciation for taxable earnings, add back the latter, then deduct cash capex and working capital. Interim earnings and diluted shares, p. 46 Interim cash flows, rent and capital purchases, p. 50 · Highlighted Peralta exhibit
Growth
Reported trailing sales are C$65.769 billion over 53 weeks. Remove C$1.138 billion, allocated proportionally to FY2025 category sales, giving C$64.631 billion on a 52-week basis. First forward-year food, pharmacy and front-store growth is 3.5%, 7.5% and 2.5%, fading to 2.5%, 3.5% and 2.0%. Category allocation of the extra week is estimated. FY2025 category sales and 53rd-week adjustment, p. 32 · Highlighted Peralta exhibit Q3 sales by category and comparable store sales, p. 12 · Highlighted Peralta exhibit
Profitability
We assume an 11.2% pre-rent EBITDA margin versus Q3 adjusted EBITDA margin of 11.3%. Adjusted EBITDA is a cross-check and includes issuer adjustments. The model separately expenses cash rent at 2.65% of sales and depreciates owned assets at 1.8%. The normalization is an estimate, not an issuer forecast. Interim cash flows, rent and capital purchases, p. 50 · Highlighted Peralta exhibit Adjusted EBITDA margin, p. 8
Reinvestment or Required Capital
Forecast nominal CAD capex at 3.7% falling to 3.2% of sales, and working-capital cash use at 0.1% of sales. The latter smooths a volatile C$235 million interim outflow. Taxes take 27% of normalized operating profit after rent. Management outlook and gross capital expenditure, p. 28 Interim cash flows, rent and capital purchases, p. 50 · Highlighted Peralta exhibit Interim earnings and diluted shares, p. 46
Discount Rate
The 7.4% WACC approximates 90% equity at 7.81% and 10% debt at 5.0% before 27% tax. Equity uses the Nov 19 Canada ten-year yield of 3.81%, assumed 0.8 beta and 5% equity premium. Capital weights and risk inputs are analyst estimates; the 100 bp discount-rate alternative tests the combined choice. Bank of Canada, 10-year benchmark yield, Nov 19 Note 10, borrowings and available facilities, p. 59
Terminal Economics
Forecast periods run from the November 19 valuation date in twelve-month increments, using October accounts as a run-rate proxy. From year eleven, FCFF grows 2.5%. Terminal PV supplies 64% of enterprise value, so persistent capex and cash margin matter more than a single-quarter beat. Annual cash flows
Bridge to One Common Share
| Forward year | Food | Pharmacy | Front store | Sales | EBITDA | Cash rent | Owned D&A | NOPAT | Capex | Working capital use | FCFF | PV factor | PV FCFF |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 47,124 | 11,164 | 8,933 | 67,221 | 7,529 | 1,781 | 1,210 | 3,312 | 2,487 | 67 | 1,968 | 0.9311 | 1,832 |
| 2 | 48,706 | 11,937 | 9,150 | 69,794 | 7,817 | 1,850 | 1,256 | 3,439 | 2,513 | 70 | 2,113 | 0.8669 | 1,832 |
| 3 | 50,272 | 12,696 | 9,366 | 72,334 | 8,101 | 1,917 | 1,302 | 3,564 | 2,532 | 72 | 2,262 | 0.8072 | 1,826 |
| 4 | 51,816 | 13,431 | 9,580 | 74,827 | 8,381 | 1,983 | 1,347 | 3,687 | 2,544 | 75 | 2,415 | 0.7516 | 1,815 |
| 5 | 53,333 | 14,131 | 9,792 | 77,257 | 8,653 | 2,047 | 1,391 | 3,807 | 2,549 | 77 | 2,571 | 0.6998 | 1,799 |
| 6 | 54,819 | 14,787 | 10,002 | 79,608 | 8,916 | 2,110 | 1,433 | 3,923 | 2,547 | 80 | 2,729 | 0.6516 | 1,778 |
| 7 | 56,268 | 15,389 | 10,209 | 81,866 | 9,169 | 2,169 | 1,474 | 4,034 | 2,620 | 82 | 2,806 | 0.6067 | 1,702 |
| 8 | 57,674 | 15,928 | 10,413 | 84,016 | 9,410 | 2,226 | 1,512 | 4,140 | 2,689 | 84 | 2,880 | 0.5649 | 1,627 |
| 9 | 59,116 | 16,485 | 10,622 | 86,223 | 9,657 | 2,285 | 1,552 | 4,249 | 2,759 | 86 | 2,955 | 0.5260 | 1,554 |
| 10 | 60,594 | 17,062 | 10,834 | 88,491 | 9,911 | 2,345 | 1,593 | 4,360 | 2,832 | 88 | 3,033 | 0.4897 | 1,485 |
| Value bridge | C$ millions unless stated |
|---|---|
| PV explicit FCFF | 17,251.13 |
| PV terminal FCFF | 31,071.33 |
| Retail enterprise value | 48,322.46 |
| Cash | 1,049.00 |
| Equity-accounted investments | 1,262.00 |
| Financial debt | -6,105.00 |
| Associate interest | -384.00 |
| Noncontrolling equity | -171.00 |
| Common equity | 43,973.46 |
| Diluted shares, millions | 1,160.70 |
| Fair value per share | 37.89 |
Cash rent includes lease principal and interest, so the bridge deducts financial borrowings and omits lease debt. Treat C$384 million of associate interest as a claim and use NCI book value as a proxy. Carry equity investments at C$1.262 billion without their earnings in EBIT. Use the latest quarterly diluted average of 1,160.7 million shares. Book values and October positions approximate November values. Interim balance sheets, p. 49 · Highlighted Peralta exhibit Note 9, EQB and other investments, p. 58 Note 11, common-share movements, p. 60 Interim earnings and diluted shares, p. 46
Price-Implied Expectations
With the discount rate and revenue path fixed, solving the DCF at C$70.92 gives 14.86% EBITDA margin versus our 11.2%. This is one price-implied combination. A lower discount rate and less reinvestment can support a higher price together. Loblaw TSX daily closing prices
Independent Cross-Check
Trailing continuing diluted EPS approximates C$2.31 (2.11 + 1.79 − 1.59). The close implies 30.7× and base value 16.4×. Metro trades at 23.1× FY2026 diluted EPS of C$4.18 using its November 19 close of C$96.72; applying that multiple gives roughly C$53.45. This independent check is above DCF and below market. Season length, growth, lease mix and denominator weights differ. Annual earnings from continuing and discontinued operations, p. 102 Interim earnings and diluted shares, p. 46 Metro earnings and cash operating costs, p. 17 Metro price history
Conclusion and Change from Prior Edition
The entry uses the least of base value, persistent margin stress and a five-year 9.5% return ceiling, rounded down to a cent. The benchmark assumption is 7.5% annual after cost plus 2 points required spread; it is a policy scenario, not a measured XIC forecast. No preceding Loblaw edition was found.
Peer Selection
Metro overlaps in food and pharmacy; Empire supplies a grocery-led comparison. Compare operations independently of different share counts, store models and financing. Metro earnings and cash operating costs, p. 17 Empire earnings and equity income, p. 27
Dated Ratio Table
| Issuer / latest quarter | Sales C$m | Operating margin | Parent net margin, total operations |
|---|---|---|---|
| Loblaw | 19,857.0 | 7.09% | 6.01% |
| Metro | 5,179.5 | 5.96% | 3.88% |
| Empire | 8,475.0 | 4.85% | 2.75% |
Latest reported quarters available on November 19: Loblaw 16 weeks to October 10, Metro 12 weeks to September 26 and Empire 13 weeks to August 1. Each column divides same-quarter profit by sales. Interim earnings and diluted shares, p. 46 Metro earnings and cash operating costs, p. 17 Empire earnings and equity income, p. 27
Comparability Adjustments
Metro EBIT here is pretax income plus net financial costs. Empire’s reported operating income includes equity income. Loblaw parent net margin includes the PC Financial sale and consequently overstates recurring margin. Metro earnings and cash operating costs, p. 17 Empire earnings and equity income, p. 27 Note 4, discontinued earnings and sale gain, p. 54 · Highlighted Peralta exhibit
Implications for Value
The category supports a retail margin premium, but relative reported earnings also challenge our conservative DCF. At Metro’s trailing multiple the implied Loblaw value remains around C$53; the model’s C$33.36 entry demands materially better cash yield. Metro earnings and cash operating costs, p. 17 Annual earnings from continuing and discontinued operations, p. 102 Interim earnings and diluted shares, p. 46
Bear Case
Bear assumes a permanent 80 bp cash-margin loss, one point less annual category growth and a one-point higher discount rate. Fair value falls to C$22.54, a 32.4% loss even at base entry.
Base Case
Base forecasts pharmacy growth above food growth before both mature. A C$37.89 fair value leaves 13.6% upside from the base entry before distributions.
Bull Case
Bull adds half a margin point and one growth point while cutting WACC by half a point. Even that operating case reaches only C$52.15; the discount-rate evidence below is a stronger challenge.
Outcomes at Close and Entry
| Assumption | Close | Fair value | Maximum entry | Price rule |
|---|---|---|---|---|
| Base | 70.92 | 37.89 | 33.36 | Wait |
| Margin down 50 bp | 70.92 | 33.37 | 28.85 | Wait |
| Discount rate down 100 bp | 70.92 | 48.81 | 41.67 | Wait |
| Bull | 70.92 | 52.15 | 45.52 | Wait |
| Bear | 70.92 | 22.54 | 19.07 | Wait |
| 52-week observed beta | 70.92 | 116.55 | 90.29 | Buy |
| 156-week observed beta | 70.92 | 83.80 | 66.79 | Wait |
| Case | Fair value vs close | Fair value vs base entry | 5y annual return at close |
|---|---|---|---|
| Base | -46.6% | 13.6% | -5.57% |
| Margin down 50 bp | -52.9% | 0.0% | -7.91% |
| Discount rate down 100 bp | -31.2% | 46.3% | -1.55% |
| Bull | -26.5% | 56.3% | 0.21% |
| Bear | -68.2% | -32.4% | -14.05% |
| 52-week observed beta | 64.3% | 249.4% | 14.92% |
| 156-week observed beta | 18.2% | 151.2% | 8.20% |
Year-five exit is the value at year five of remaining operating cash flows plus the same balance-sheet bridge. Estimated first-five-year distributable cash deducts after-tax financial interest. We assume this cash reaches investors and is held uninvested, with 10 bp each way on trading, constant net claims and no tax at investor level. This is a payout-equivalent scenario. Actual dividends and buybacks differ.
Market-Implied Case
| Weekly returns | First week | Last week | L vs XIC beta | WACC | Fair CAD | Entry CAD |
|---|---|---|---|---|---|---|
| 52 | 2025-11-10 | 2026-11-09 | 0.095 | 4.22% | 116.55 | 90.29 |
| 156 | 2023-11-13 | 2026-11-09 | 0.237 | 4.86% | 83.80 | 66.79 |
Changing only the discount-rate calibration flips the conclusion at the 52-week beta. The 156-week estimate also puts fair value above the market, although the margin-stressed or hurdle-limited entry stays below the close. These are overlapping samples of one defensive company against a Canadian index. Frozen adjusted series
Analyst Assessment
The one-year beta implies 4.22% WACC and leaves only 1.72 percentage points above perpetual growth. That small denominator makes the C$90.29 entry fragile. We retain the more conservative policy beta as an explicit judgment pending evidence on long-run risk. The range C$33–90 matters more than cent precision.
Operating Risks
Lower food traffic can require promotions, which may raise revenue while cutting gross margin. Watch whether the 0.6% same-store food growth turns negative as the network expands. Q3 sales by category and comparable store sales, p. 12 · Highlighted Peralta exhibit
Financial and Liquidity Risks
The C$6.10 billion financial debt balance excludes lease liabilities, but rent still consumes cash. Forecast rent above 2.65% of sales reduces FCFF and should trigger a rerun. Note 10, borrowings and available facilities, p. 59 Interim cash flows, rent and capital purchases, p. 50 · Highlighted Peralta exhibit
Regulatory and Legal Risks
Pharmacy economics depend on reimbursement and product mix. Review any material rate change against the C$3.20 billion quarterly pharmacy and health revenue base before changing margin. Q3 sales by category and comparable store sales, p. 12 · Highlighted Peralta exhibit
Industry and Competitive Risks
Metro’s current financial statements show a lower latest-quarter margin. A narrowing spread may reflect competition or timing, so compare multiple quarters and cash margins. Metro earnings and cash operating costs, p. 17 Interim earnings and diluted shares, p. 46
Thesis-Specific Risks and Reconsideration Triggers
Reopen the wait decision if sustained margins move toward 14.9%, capital spending normalizes below 3.2% of sales, or a defensible long-duration cost of capital falls near the empirical estimates. Reassess the denominator as well as growth. Management outlook and gross capital expenditure, p. 28 Bank of Canada, 10-year benchmark yield, Nov 19
Environmental Factors
The proxy links emissions reduction and food-waste diversion projects to incentive measures. Model refrigeration and store retrofit spending in capex; the disclosure does not isolate an incremental per-share benefit. Climate and waste incentive scorecard, p. 66
Social Factors
Pharmacy care delivery requires qualified staff. Sustained wage pressure would first show in selling and administrative costs relative to prescription sales. We model the exposure through cash margin. Q3 sales by category and comparable store sales, p. 12 · Highlighted Peralta exhibit Interim earnings and diluted shares, p. 46
Governance Factors
Weston controls the shareholder vote. Capital allocation can favor long-horizon investments, while minority investors have limited ability to change board composition independently. Record-date voting rights and beneficial ownership, p. 11 · Highlighted Peralta exhibit
Financially Material Risks and Opportunities
Waste reduction could improve gross margin, while energy upgrades require upfront cash. Revisit only on disclosed savings or expenditures; neither receives a separate terminal premium. Climate and waste incentive scorecard, p. 66
Annual Results
| C$ million | FY2024 | FY2025 |
|---|---|---|
| Sales | 60,123 | 63,903 |
| Operating income | 3,474 | 4,424 |
| Continuing net income | 2,060 | 2,602 |
| Discontinued net income | 215 | 136 |
FY2025 ended January 3, 2026 and includes 53 weeks. FY2024 ended December 28, 2024. Comparative continuing operations are restated. Annual earnings from continuing and discontinued operations, p. 102
Interim Results
| C$ million | 2025 comparative | 2026 current |
|---|---|---|
| Sales | 47,521 | 49,387 |
| Operating income | 3,290 | 3,620 |
| Continuing net income | 1,998 | 2,182 |
| Discontinued net income | 91 | 439 |
Forty weeks ended October 10, 2026 versus October 4, 2025. EBIT increased faster than sales. Interim earnings and diluted shares, p. 46
Trailing Results
| C$ million | 53 weeks to Oct 10 2026 |
|---|---|
| Sales | 65,769 |
| Operating income | 4,754 |
| Continuing net income | 2,786 |
| Discontinued net income | 484 |
Annual plus current interim less prior comparable interim. Retain 53 weeks here to reconcile the published periods. Annual earnings from continuing and discontinued operations, p. 102 Interim earnings and diluted shares, p. 46
Material Adjustments
Remove the extra retail week only for forecast sales. Remove discontinued earnings when comparing earnings power. The EQB investment appears separately in the equity bridge. FY2025 category sales and 53rd-week adjustment, p. 32 · Highlighted Peralta exhibit Note 4, discontinued earnings and sale gain, p. 54 · Highlighted Peralta exhibit Note 9, EQB and other investments, p. 58
Annual Positions
| C$ million | FY2024 | FY2025 |
|---|---|---|
| Cash | 1,462 | 1,002 |
| Inventory | 6,330 | 6,491 |
| Total assets | 40,880 | 41,577 |
| Total liabilities | 29,614 | 30,385 |
| Total equity | 11,266 | 11,192 |
Year-end balances at December 28, 2024 and January 3, 2026. Assets held for sale affect year-over-year comparisons. Annual balance sheets, p. 105
Interim Positions
| C$ million | 2025 comparative | 2026 current |
|---|---|---|
| Cash | 1,350 | 1,049 |
| Inventory | 6,750 | 6,883 |
| Total assets | 41,563 | 38,732 |
| Total liabilities | 30,007 | 27,017 |
| Total equity | 11,556 | 11,715 |
Snapshots as at October 4, 2025 and October 10, 2026. Both periods balance without adding annual and interim balances. Interim balance sheets, p. 49 · Highlighted Peralta exhibit
Capital and Claims Reconciliation
Cash of C$1.049 billion offsets financial debt, while lease obligations are serviced through modeled cash rent. The valuation adds associates at carrying amount; a 25% haircut on C$1.262 billion would reduce value by roughly C$0.27 per share. Interim balance sheets, p. 49 · Highlighted Peralta exhibit Note 9, EQB and other investments, p. 58
Annual Flows
| C$ million | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | 5,802 | 6,264 |
| Fixed asset purchases | 1,823 | 1,712 |
| Intangible additions | 377 | 350 |
| Cash interest paid, excluding lease interest | 443 | 455 |
| Lease principal | 1,086 | 1,255 |
| Lease interest | 415 | 453 |
| Cash dividends | 459 | 812 |
| Shares purchased and cancelled | 1,754 | 1,875 |
FY2024 and FY2025 reported total operations. Purchases, rent and payments are shown as positive uses. Annual cash flows and shareholder distributions, p. 106
Interim Flows
| C$ million | 2025 comparative | 2026 current |
|---|---|---|
| Operating cash flow | 4,067 | 5,051 |
| Fixed asset purchases | 1,078 | 1,223 |
| Intangible additions | 262 | 295 |
| Cash interest paid, excluding lease interest | 344 | 331 |
| Lease principal | 964 | 887 |
| Lease interest | 348 | 353 |
| Cash dividends | 646 | 522 |
| Shares purchased and cancelled | 1,280 | 1,721 |
Forty weeks in each period. Buybacks used C$1.72 billion, exceeding C$522 million cash dividends. Interim cash flows, rent and capital purchases, p. 50 · Highlighted Peralta exhibit
Trailing Flows
| C$ million | 53 weeks to Oct 10 2026 |
|---|---|
| Operating cash flow | 7,248 |
| Fixed asset purchases | 1,857 |
| Intangible additions | 383 |
| Cash interest paid, excluding lease interest | 442 |
| Lease principal | 1,178 |
| Lease interest | 458 |
| Cash dividends | 688 |
| Shares purchased and cancelled | 2,316 |
The 53-week cash-flow bridge includes discontinued operations until sale. We do not extrapolate that consolidated cash balance as ongoing retail FCFF. Annual cash flows and shareholder distributions, p. 106 Interim cash flows, rent and capital purchases, p. 50 · Highlighted Peralta exhibit Note 4, discontinued earnings and sale gain, p. 54 · Highlighted Peralta exhibit
Reconciliation to Common Shareholders
For the current 40 weeks, C$5,051m operating cash less C$1,518m fixed and intangible purchases, C$1,240m lease cash and C$331m other cash interest leaves C$1,962m before other claims, financing and portfolio activity. Common and preferred dividends plus buybacks totalled C$2,243m; these periods need not fund all distributions internally. For comparison, the issuer reports continuing free cash flow of C$1,612m after capital investment, net lease payments and interest, against C$1,962m on our total-operations cash basis. Issuer FCF reconciliation, p. 19 Interim cash flows, rent and capital purchases, p. 50 · Highlighted Peralta exhibit
Primary Sources and Locators
The source ledger maps the decision to issuer rows, reported periods, comparables and analyst assumptions. Primary issuer documents are linked at each point of use. FY2025 category sales and 53rd-week adjustment, p. 32 · Highlighted Peralta exhibit Q3 sales by category and comparable store sales, p. 12 · Highlighted Peralta exhibit Metro earnings and cash operating costs, p. 17 Empire earnings and equity income, p. 27
Frozen Inputs and Assumptions
The frozen operating inputs, dated closes and adjusted weekly pairs reproduce the decision. Weekly pairs are date, L.TO, XIC.TO in CAD. Each date labels the beginning of the completed trading week. Category rates, risk premiums and terminal growth are assumptions.
Worksheets and Saved Outputs
From support/ run python valuation.py, python statements.py, then python beta.py. Python 3.12 standard library. Amounts in CAD millions except prices and share counts as labeled.
Changes from the Preceding Edition
First edition without a predecessor. No public historical Loblaw edition appeared in the Peralta edition index at review.
Closing prices
| Trading date | Close (CAD) |
|---|---|
| 2025-11-20 | 62.17 |
| 2025-11-21 | 63.03 |
| 2025-11-24 | 61.89 |
| 2025-11-25 | 63.02 |
| 2025-11-26 | 62.65 |
| 2025-11-27 | 62.70 |
| 2025-11-28 | 62.00 |
| 2025-12-01 | 62.60 |
| 2025-12-02 | 61.70 |
| 2025-12-03 | 60.84 |
| 2025-12-04 | 62.17 |
| 2025-12-05 | 62.17 |
| 2025-12-08 | 61.82 |
| 2025-12-09 | 61.42 |
| 2025-12-10 | 61.27 |
| 2025-12-11 | 61.42 |
| 2025-12-12 | 61.21 |
| 2025-12-15 | 61.61 |
| 2025-12-16 | 61.61 |
| 2025-12-17 | 61.76 |
| 2025-12-18 | 62.48 |
| 2025-12-19 | 61.86 |
| 2025-12-22 | 61.89 |
| 2025-12-23 | 61.55 |
| 2025-12-24 | 61.45 |
| 2025-12-29 | 61.91 |
| 2025-12-30 | 62.01 |
| 2025-12-31 | 62.05 |
| 2026-01-02 | 62.09 |
| 2026-01-05 | 61.31 |
| 2026-01-06 | 60.91 |
| 2026-01-07 | 60.80 |
| 2026-01-08 | 61.04 |
| 2026-01-09 | 61.84 |
| 2026-01-12 | 62.75 |
| 2026-01-13 | 62.34 |
| 2026-01-14 | 62.88 |
| 2026-01-15 | 62.30 |
| 2026-01-16 | 62.58 |
| 2026-01-19 | 62.49 |
| 2026-01-20 | 61.91 |
| 2026-01-21 | 62.70 |
| 2026-01-22 | 62.37 |
| 2026-01-23 | 62.96 |
| 2026-01-26 | 62.44 |
| 2026-01-27 | 61.63 |
| 2026-01-28 | 61.37 |
| 2026-01-29 | 61.94 |
| 2026-01-30 | 61.27 |
| 2026-02-02 | 62.92 |
| 2026-02-03 | 65.46 |
| 2026-02-04 | 67.00 |
| 2026-02-05 | 66.77 |
| 2026-02-06 | 67.09 |
| 2026-02-09 | 66.79 |
| 2026-02-10 | 65.77 |
| 2026-02-11 | 66.28 |
| 2026-02-12 | 67.96 |
| 2026-02-13 | 67.86 |
| 2026-02-17 | 68.49 |
| 2026-02-18 | 68.67 |
| 2026-02-19 | 68.58 |
| 2026-02-20 | 67.26 |
| 2026-02-23 | 69.26 |
| 2026-02-24 | 67.52 |
| 2026-02-25 | 63.80 |
| 2026-02-26 | 64.11 |
| 2026-02-27 | 63.22 |
| 2026-03-02 | 63.79 |
| 2026-03-03 | 63.24 |
| 2026-03-04 | 62.47 |
| 2026-03-05 | 61.89 |
| 2026-03-06 | 62.29 |
| 2026-03-09 | 63.09 |
| 2026-03-10 | 63.14 |
| 2026-03-11 | 62.09 |
| 2026-03-12 | 62.08 |
| 2026-03-13 | 63.32 |
| 2026-03-16 | 64.38 |
| 2026-03-17 | 63.78 |
| 2026-03-18 | 63.12 |
| 2026-03-19 | 61.87 |
| 2026-03-20 | 61.86 |
| 2026-03-23 | 63.29 |
| 2026-03-24 | 62.58 |
| 2026-03-25 | 62.42 |
| 2026-03-26 | 62.23 |
| 2026-03-27 | 63.09 |
| 2026-03-30 | 63.67 |
| 2026-03-31 | 63.42 |
| 2026-04-01 | 64.04 |
| 2026-04-02 | 64.59 |
| 2026-04-06 | 64.76 |
| 2026-04-07 | 64.57 |
| 2026-04-08 | 65.17 |
| 2026-04-09 | 63.76 |
| 2026-04-10 | 63.21 |
| 2026-04-13 | 62.20 |
| 2026-04-14 | 61.38 |
| 2026-04-15 | 62.19 |
| 2026-04-16 | 61.02 |
| 2026-04-17 | 61.19 |
| 2026-04-20 | 61.69 |
| 2026-04-21 | 62.23 |
| 2026-04-22 | 61.95 |
| 2026-04-23 | 62.07 |
| 2026-04-24 | 62.67 |
| 2026-04-27 | 61.77 |
| 2026-04-28 | 61.96 |
| 2026-04-29 | 62.17 |
| 2026-04-30 | 62.62 |
| 2026-05-01 | 62.72 |
| 2026-05-04 | 61.98 |
| 2026-05-05 | 63.16 |
| 2026-05-06 | 59.73 |
| 2026-05-07 | 60.10 |
| 2026-05-08 | 60.81 |
| 2026-05-11 | 59.06 |
| 2026-05-12 | 60.31 |
| 2026-05-13 | 60.23 |
| 2026-05-14 | 60.92 |
| 2026-05-15 | 60.66 |
| 2026-05-19 | 61.40 |
| 2026-05-20 | 61.50 |
| 2026-05-21 | 61.57 |
| 2026-05-22 | 61.43 |
| 2026-05-25 | 61.46 |
| 2026-05-26 | 60.50 |
| 2026-05-27 | 61.39 |
| 2026-05-28 | 61.69 |
| 2026-05-29 | 61.67 |
| 2026-06-01 | 62.29 |
| 2026-06-02 | 61.62 |
| 2026-06-03 | 62.80 |
| 2026-06-04 | 63.24 |
| 2026-06-05 | 65.53 |
| 2026-06-08 | 64.73 |
| 2026-06-09 | 66.30 |
| 2026-06-10 | 66.47 |
| 2026-06-11 | 66.68 |
| 2026-06-12 | 65.00 |
| 2026-06-15 | 64.59 |
| 2026-06-16 | 64.88 |
| 2026-06-17 | 64.69 |
| 2026-06-18 | 64.76 |
| 2026-06-19 | 64.09 |
| 2026-06-22 | 63.38 |
| 2026-06-23 | 64.77 |
| 2026-06-24 | 66.20 |
| 2026-06-25 | 66.09 |
| 2026-06-26 | 65.93 |
| 2026-06-29 | 64.59 |
| 2026-06-30 | 64.34 |
| 2026-07-02 | 62.87 |
| 2026-07-03 | 62.45 |
| 2026-07-06 | 61.69 |
| 2026-07-07 | 63.04 |
| 2026-07-08 | 63.92 |
| 2026-07-09 | 63.39 |
| 2026-07-10 | 64.18 |
| 2026-07-13 | 64.96 |
| 2026-07-14 | 64.18 |
| 2026-07-15 | 64.08 |
| 2026-07-16 | 65.12 |
| 2026-07-17 | 65.49 |
| 2026-07-20 | 65.48 |
| 2026-07-21 | 64.98 |
| 2026-07-22 | 64.55 |
| 2026-07-23 | 63.39 |
| 2026-07-24 | 64.35 |
| 2026-07-27 | 64.97 |
| 2026-07-28 | 66.13 |
| 2026-07-29 | 66.03 |
| 2026-07-30 | 65.70 |
| 2026-07-31 | 65.81 |
| 2026-08-04 | 65.31 |
| 2026-08-05 | 64.09 |
| 2026-08-06 | 63.30 |
| 2026-08-07 | 62.89 |
| 2026-08-10 | 61.97 |
| 2026-08-11 | 62.09 |
| 2026-08-12 | 61.86 |
| 2026-08-13 | 62.63 |
| 2026-08-14 | 61.91 |
| 2026-08-17 | 60.79 |
| 2026-08-18 | 60.88 |
| 2026-08-19 | 61.79 |
| 2026-08-20 | 60.97 |
| 2026-08-21 | 60.53 |
| 2026-08-24 | 61.56 |
| 2026-08-25 | 61.25 |
| 2026-08-26 | 61.45 |
| 2026-08-27 | 60.61 |
| 2026-08-28 | 60.42 |
| 2026-08-31 | 60.64 |
| 2026-09-01 | 62.10 |
| 2026-09-02 | 62.08 |
| 2026-09-03 | 62.44 |
| 2026-09-04 | 63.31 |
| 2026-09-08 | 62.71 |
| 2026-09-09 | 62.43 |
| 2026-09-10 | 61.46 |
| 2026-09-11 | 61.28 |
| 2026-09-14 | 63.05 |
| 2026-09-15 | 61.61 |
| 2026-09-16 | 62.73 |
| 2026-09-17 | 62.78 |
| 2026-09-18 | 61.80 |
| 2026-09-21 | 62.34 |
| 2026-09-22 | 62.85 |
| 2026-09-23 | 61.90 |
| 2026-09-24 | 62.15 |
| 2026-09-25 | 62.71 |
| 2026-09-28 | 62.99 |
| 2026-09-29 | 62.47 |
| 2026-09-30 | 62.20 |
| 2026-10-01 | 62.19 |
| 2026-10-02 | 62.16 |
| 2026-10-05 | 61.79 |
| 2026-10-06 | 61.41 |
| 2026-10-07 | 62.22 |
| 2026-10-08 | 62.68 |
| 2026-10-09 | 62.64 |
| 2026-10-13 | 63.93 |
| 2026-10-14 | 65.72 |
| 2026-10-15 | 69.00 |
| 2026-10-16 | 70.06 |
| 2026-10-19 | 68.72 |
| 2026-10-20 | 69.09 |
| 2026-10-21 | 68.46 |
| 2026-10-22 | 70.66 |
| 2026-10-23 | 68.67 |
| 2026-10-26 | 68.92 |
| 2026-10-27 | 68.15 |
| 2026-10-28 | 67.98 |
| 2026-10-29 | 68.50 |
| 2026-10-30 | 69.07 |
| 2026-11-02 | 69.63 |
| 2026-11-03 | 69.32 |
| 2026-11-04 | 70.43 |
| 2026-11-05 | 68.97 |
| 2026-11-06 | 69.45 |
| 2026-11-09 | 69.39 |
| 2026-11-10 | 68.99 |
| 2026-11-11 | 69.11 |
| 2026-11-12 | 69.35 |
| 2026-11-13 | 69.93 |
| 2026-11-16 | 71.04 |
| 2026-11-17 | 71.09 |
| 2026-11-18 | 70.57 |
| 2026-11-19 | 70.92 |